Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study

The Lancet Global Health

Volumn 6, Issue 7, 2018, Pages e804-e810

  Zash, Rebecca ^a   Jacobson, Denise L ^b   Diseko, Modiegi ^d   Mayondi, Gloria ^d   Mmalane, Mompati ^d   Essex, Max ^c   Gaolethe, Tendani ^d   Petlo, Chipo ^e   Lockman, Shahin ^f   Holmes, Lewis B ^g   Makhema, Joseph ^d   Shapiro, Roger L ^c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^e Department of HIV AIDS Prevention and Care   (Botswana)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOLUTEGRAVIR; EFAVIRENZ; ANTIRETROVIRUS AGENT; BENZOXAZINE DERIVATIVE; FUSED HETEROCYCLIC RINGS;

ADULT; ADVERSE OUTCOME; ANTIRETROVIRAL THERAPY; ARTICLE; ATTRIBUTABLE RISK; BIRTH WEIGHT; BOTSWANA; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; NEWBORN DEATH; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE LABOR; PRENATAL CARE; RISK FACTOR; SMALL FOR DATE INFANT; STILLBIRTH; COMPARATIVE STUDY; EPIDEMIOLOGY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PREGNANCY COMPLICATION; YOUNG ADULT;

ADULT; ANTI-RETROVIRAL AGENTS; BENZOXAZINES; BOTSWANA; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; YOUNG ADULT;

EID: 85048292450     PISSN: None     EISSN: 2214109X     Source Type: Journal    
DOI: 10.1016/S2214-109X(18)30218-3     Document Type: Article

References (21)

1. Günthard, HF, Saag, MS, Benson, CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults [2016] recommendations of the International Antiviral Society—USA Panel. JAMA 316 (2016), 191–210.
2. Department for Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf, 2016. (Accessed 8 November 2017)
3. Venter, F, Kaiser, B, Pillay, Y, et al. Cutting the cost of South African antiretroviral therapy using newer, safer drugs. South Afr Med J 107 (2017), 28–30.
4. Barnhart, M, Shelton, J, ARVs: the next generation. Going boldly together to new frontiers of HIV treatment. Glob Health Sci Prac 1 (2015), 1–11.
5. Vitoria, M, Ford, N, Claden, P, Pozniak, A, Hill, A, When could new antiretrovirals be recommended for national treatment programs in low and middle income countries: results of a WHO think tank. Curr Op HIV AIDS 12 (2017), 414–422.
6. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry Interim Report for 1 January 1989 through 31 July 2017. 2017, Registry Coordinating Center, Wilmington, NC.
7. Zash, R, Souda, S, Chen, JY, et al. Reassuring birth outcomes with tenofovir/emtricitabine/efavirenz used for prevention of mother-to-child transmission of HIV in Botswana. J Acquir Immune Defic Syndr 71 (2016), 428–436.
8. Zash, R, Jacobson, DL, Diseko, M, et al. Comparative safety of antiretroviral treatment regimens in pregnancy. JAMA Pediatr, 171, 2017, e172222.
9. Botswana Ministry of Health. Handbook of the Botswana 2016 Integrated HIV Clinical Care Guidelines. http://apps.who.int/medicinedocs/documents/s22413en/s22413en.pdf, 2016. (Accessed 8 November 2017)
10. Statistics Botswana. Health Statistics Report 2009. 2012, Statistics Botswana, Gaborone.
11. Botswana Ministry of Health. 2012 Botswana National HIV & AIDS Treatment Guidelines. 2012, Botswana Ministry of Health, Gaborone.
12. Villar, J, Cheikh Ismail, L, Victora, CG, et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. Lancet 384 (2014), 857–868.
13. Villar, J, Giuliani, F, Fenton, TR, et al. INTERGROWTH-21st very preterm size at birth reference charts. Lancet 387 (2016), 844–845.
14. Thorne C, Favarato G, Peters H, et al. Pregnancy and neonatal outcomes following prenatal exposure to dolutegravir. 9th IAS Conference on HIV Science; Paris, France; July 23–26, 2017. 4549.
15. Sibiude J, Warszawski J, Blanche S, et al. Evaluation of the risk of birth defects among children exposed to raltegravir in utero in the ANRS-French Perinatal Cohort EPF. 9th IAS Conference on HIV Science; Paris, France; July 23–26, 2017. 3037.
16. Mulligan N, Best B, Capparelli E, et al. Dolutegravir pharmacokinetics in HIV-infected pregnant and postpartum women. Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; February 22–25, 2016. 438.
17. Thorne C, Favarato G, Peters H, et al. Pregnancy and neonatal outcomes following prenatal exposure to dolutegravir. 9th IAS Conference on HIV Science; Paris, France; July 23–26, 2017. 4549.
18. Watson, B, Hennrikus, W, Postaxial type-B polydactyly. Prevalence and treatment. J Bone Joint Surg Am 79 (1997), 65–68.
19. Chen, JY, Ribaudo, HJ, Souda, S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis 206 (2012), 1695–1705.
20. Cohen, MS, Chen, YQ, McCauley, M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365 (2011), 493–505.
21. Turner, AN, Tabbah, S, Mwapasa, V, et al. Severity of maternal HIV-1 disease is associated with adverse birth outcomes in Malawian women: a cohort study. J Acquir Immune Defic Syndr 64 (2013), 392–399.